Skip to main navigation Skip to search Skip to main content

Mechanistic/mammalian target of rapamycin: Recent pathological aspects and inhibitors

  • Mohammed S. Abdel-Maksoud
  • , Mohammed I. El-Gamal
  • , Dalia Reyane Benhalilou
  • , Sandy Ashraf
  • , Shatha Abdulghaffar Mohammed
  • , Chang Hyun Oh
  • National Research Center
  • Faculty of Pharmacy
  • University of Sharjah
  • Korea Institute of Science and Technology
  • University of Science and Technology UST

Research output: Contribution to journalReview articlepeer-review

34 Scopus citations

Abstract

The mechanistic/mammalian target of rapamycin (mTOR), also known as the mechanistic target of rapamycin, regulates many normal cell processes such as transcription, cell growth, and autophagy. Overstimulation of mTOR by its ligands, amino acids, sugars, and/or growth factors leads to physiological disorders, including cancer and neurodegenerative diseases. In this study, we reviewed the recent advances regarding the mechanism that involves mTOR in cancer, aging, and neurodegenerative diseases. The chemical and biological properties of recently reported small molecules that function as mTOR kinase inhibitors, including adenosine triphosphate-competitive inhibitors and dual mTOR/PI3K inhibitors, have also been reviewed. We focused on the reports published in the literature from 2012 to 2017.

Original languageEnglish
Pages (from-to)631-664
Number of pages34
JournalMedicinal Research Reviews
Volume39
Issue number2
DOIs
StatePublished - Mar 2019

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • PI3K
  • aging
  • anticancer
  • kinase inhibitors
  • mTOR

Fingerprint

Dive into the research topics of 'Mechanistic/mammalian target of rapamycin: Recent pathological aspects and inhibitors'. Together they form a unique fingerprint.

Cite this